Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Summary

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

Eligibility

Inclusion Criteria:

* Histologically confirmed type AB or B1-3 thymoma.
* Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
* Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
* Between the ages of 18 and 70 years, regardless of sex.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* No prior chest radiation.
* Adequate organ Functions.
* Written informed consent obtained.

Exclusion Criteria:

* Contraindications to Methylprednisolone.
* History of or Concurrent Malignancy.
* Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.
* Pregnant or Lactating Women.
* Bleeding Disorders.
* Recent Participation in Other Clinical Trials.
* Drug Abuse or Severe Alcoholism.
* Uncontrolled Seizures or Mental Disorders.
* Severe Allergies or Specific Sensitivities.

Conditions2

Interventions2

Related trials

• A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI — Sun Yat-sen University
• Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer — Sun Yat-sen University
• Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer — Samsung Medical Center
• Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
• Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC — Sun Yat-sen University
• Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma — Sun Yat-sen University
• Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy — Sun Yat-sen University

Browse More Trials